Clofazimine does not lead to significant QT interval prolongation: a multicentre study
- PMID: 30385602
- DOI: 10.1183/13993003.01386-2018
Clofazimine does not lead to significant QT interval prolongation: a multicentre study
Conflict of interest statement
Conflict of interest: S.M.H. Zweijpfenning reports grants and non-financial support for a clinical trial from Novartis and Insmed, outside the submitted work. Conflict of interest: H. van Groningen has nothing to disclose. Conflict of interest: J. van Ingen has nothing to disclose. Conflict of interest: C. Magis-Escurra has nothing to disclose. Conflict of interest: M.J. Boeree has nothing to disclose. Conflict of interest: D. Wagner has nothing to disclose. Conflict of interest: H. Bax nothing to disclose. Conflict of interest: C. Andrejak has nothing to disclose. Conflict of interest: R. Wener has nothing to disclose. Conflict of interest: A. Rahman has nothing to disclose. Conflict of interest: H. Kunst has nothing to disclose. Conflict of interest: N. Lorent has nothing to disclose. Conflict of interest: M.A. Brouwer has nothing to disclose. Conflict of interest: W. Hoefsloot reports grants from Insmed Corp, during the conduct of the study.
Comment on
-
Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.Eur Respir J. 2017 Nov 16;50(5):1701462. doi: 10.1183/13993003.01462-2017. Print 2017 Nov. Eur Respir J. 2017. PMID: 29146605 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources